Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
Ornstein MC, George L, Wei W, Diaz-Montero CM, Rayman P, Martin A, Basu A, Beckermann KE, Nizam A, Wee CE, Gilligan TD, Gupta S, Rini BI. Ornstein MC, et al. Among authors: rayman p. Clin Genitourin Cancer. 2024 Jul 31;22(6):102181. doi: 10.1016/j.clgc.2024.102181. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39208489 Free article.
Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival.
Fallah J, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Dann P, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan T, Garcia JA, Rini B, Ornstein MC, Grivas P. Fallah J, et al. Among authors: rayman p. Clin Genitourin Cancer. 2020 Dec;18(6):500-508. doi: 10.1016/j.clgc.2020.03.004. Epub 2020 Mar 19. Clin Genitourin Cancer. 2020. PMID: 32340875
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J. Najjar YG, et al. Among authors: rayman p. Clin Cancer Res. 2017 May 1;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. Epub 2016 Oct 31. Clin Cancer Res. 2017. PMID: 27799249 Free PMC article.
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P. Tzeng A, et al. Among authors: rayman pa. Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9. Target Oncol. 2018. PMID: 30267200
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
Sheng IY, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, Rini BI, Garcia JA, Grivas P, Ornstein MC. Sheng IY, et al. Among authors: rayman p. Target Oncol. 2020 Apr;15(2):211-220. doi: 10.1007/s11523-020-00707-z. Target Oncol. 2020. PMID: 32207064
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, Montero AJ. Wilkerson AD, et al. Among authors: rayman pa. Clin Cancer Res. 2024 Jan 5;30(1):82-93. doi: 10.1158/1078-0432.CCR-23-1349. Clin Cancer Res. 2024. PMID: 37882661 Free PMC article. Clinical Trial.
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Rini BI, et al. Among authors: rayman pa. Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3. Lancet Oncol. 2016. PMID: 27498080 Free PMC article. Clinical Trial.
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P. Ornstein MC, et al. Among authors: rayman p. Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Urol Oncol. 2018. PMID: 29606341 Review.
76 results